Neuroscience

Tau proteins
#Asceneuron #Ferrer #License agreement #Neurodegenerative disorders #Neurology #Orphan drugs #Tau protein

Ferrer secures worldwide rights to PSP drug

Spanish pharma company Ferrer and Swiss biotech Asceneuron have signed a licensing agreement giving Ferrer the rights to ASN90 in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.  The terms of the agreement include an upfront fee and multiple development, regulatory and commercial milestone… Read More

#Business & Investment #News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

MRI of the brain
#Clinical trial #Minoryx Therapeutics #Neurodegenerative disorders #Phase II trial

New treatment slows progression of neurodegenerative disease

Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients.  The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology, did not meet the primary outcome… Read More

#News #Trending News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News

Research laboratory
#Astex Pharmaceuticals #Cardiff University #Collaboration #Fragment-based drug discovery #Neurodegenerative disorders #Partnership

Multimillion pound collaboration targets neurodegeneration

Astex Pharmaceuticals and The Medicines Discovery Institute, Cardiff University (MDI) have agreed a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases.    The collaboration brings together the research expertise of Dr Emyr Lloyd-Evans and Dr Helen Waller-Evans in lysosomal biology, the drug discovery… Read More

#Business & Investment #News

Dr Yue Wang and Professor Jianhua Guo
#Antibiotic resistance #Antibiotics #Antidepressants #Antimicrobial resistance (AMR) #Psychiatry

Common antidepressants increase antibiotic resistance

Researchers have found a range of commonly prescribed antidepressants can increase bacteria’s resistance to antibiotic medications. A study led by Professor Jianhua Guo from University of Queensland’s Australian Centre for Water and Environmental Biotechnology focused on prescription drugs used to treat depressive disorders, anxiety disorders, and other psychological… Read More

#News

Lissodendoryx florida
#Molecular Biology #Organic chemistry #Parkinson's #Synthetic chemistry

Synthesised sea sponge molecule could fight Parkinson’s

Organic chemists at the University of California, Los Angeles (UCLA) have created the first synthetic version of a molecule recently discovered in a sea sponge that may have therapeutic benefits for Parkinson’s disease and similar disorders.  The molecule, known as lissodendoric acid A, appears to… Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Brain #Gut microbiome #Mouse models #Neurology #Neuroscience

Mouse study findings suggest new approach to treating Alzheimer’s 

Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.  Context   Researchers at Washington University School of Medicine in St Louis showed that… Read More

#News

MRI showing glioblastoma
#Brain #Cancer research #Drug repurposing #Neuroscience #Oncology

FDA-approved drug sensitises brain cancer cells to radiotherapy

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.  Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.  GBM is a… Read More

#Cancer Research #News

Lecanemab
#Alzheimer's #Biogen #Eisai #FDA #GlobalData #Monoclonal antibodies #United States

Uncertainty surrounds monoclonal antibody for Alzheimer’s

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease… Read More

#News #Regulatory

Patient speaking to psychiatrist
#Alta Neuroscience #Biomarkers #Major depressive disorder #Neuroscience #Phase II trial #Precision psychiatry #Psychiatry

Precision drug could redefine depression treatment

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More

#News

Neurons in Parkinson's disease
#Biologics / Biotechnology #Collaboration #Drug discovery #Library screening #Neurodegenerative disorders #Partnership #Sironax #X-Chem

Research partners will target neurodegenerative disease

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.   Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into… Read More

#Business & Investment #News

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

Woman having epileptic fit
#CHMP #epilepsy #Europe #Neuroscience #Rare disease

Treatment for severe form of epilepsy approved in Europe

UCB’s Fintepla (fenfluramine) oral solution has been recommended for marketing authorisation in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), a rare, severe form of epilepsy.  The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion… Read More

#News #Regulatory